Last checked at 30 Sep 2019 16:37
Renalytix AI plc
("RenalytixAI" or the "Company")
Result of AGM
Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces at its annual general meeting held earlier today, the following resolutions were passed on a show of hands with the table below summarising proxy votes:
Resolution | Votes for* | Votes against | Votes withheld | |
1. | To receive the audited accounts of the Company | 24,481,789
| 22 | 0 |
2. | To re-elect Julian Baines | 24,481,789
| 22 | 0 |
3. | To re-elect Christopher Mills | 20,570,985
| 3,910,826
| 0 |
4. | To re-elect Richard Evans | 24,481,789
| 22
| 0 |
5. | To re-elect Fergus Fleming | 24,481,789
| 22 | 0 |
6. | To elect Doctor Erik Lium | 24,481,789
| 22 | 0 |
7. | To elect James McCullough | 24,481,789
| 22 | 0 |
8. | To elect Barbara Murphy | 24,481,811
| 0 | 0 |
9. | To re-appoint the auditors PKF Littlejohn LLP and authorise the Directors to fix their remuneration | 24,481,789
| 22 | 0 |
10. | To authorise the directors to replace the existing authority to allot shares in the Company in connection with s551 of the Companies Act 2006 | 24,481,789
| 22 | 0 |
11. | To authorise the directors to allot Relevant Securities as if s561 of the Companies Act 2006 did not apply | 23,769,147
| 702,664
| 10,000 |
*Any proxy appointments, which gave discretion to the Chairman have been included in the 'For' votes total.
For further information, please contact:
Renalytix AI plc | www.renalytixai.com | ||
James McCullough, CEO | Via Walbrook PR | ||
Stifel (Nominated Adviser & Joint Broker) | Tel: 020 7710 7600 | ||
Alex Price / Jonathan Senior / Ben Maddison
| |||
N+1 Singer (Joint Broker) | Tel: 020 7496 3000 | ||
Aubrey Powell / James White / George Tzimas (Corporate Finance)Tom Salvesen / Mia Gardner (Corporate Broking) | |||
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | ||
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 | ||
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.